UK markets closed

Theravance Biopharma, Inc. (TBPH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.12-0.02 (-0.22%)
At close: 04:00PM EDT
8.88 -0.24 (-2.63%)
After hours: 04:05PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 442.87M
Enterprise value 389.60M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.78
Price/book (mrq)2.08
Enterprise value/revenue 6.78
Enterprise value/EBITDA -9.13

Trading information

Stock price history

Beta (5Y monthly) 0.35
52-week change 3-17.17%
S&P500 52-week change 322.36%
52-week high 311.98
52-week low 38.21
50-day moving average 39.07
200-day moving average 39.61

Share statistics

Avg vol (3-month) 3369.99k
Avg vol (10-day) 3368.63k
Shares outstanding 548.56M
Implied shares outstanding 648.56M
Float 815.86M
% held by insiders 114.51%
% held by institutions 1103.31%
Shares short (15 Apr 2024) 46.43M
Short ratio (15 Apr 2024) 414.32
Short % of float (15 Apr 2024) 426.03%
Short % of shares outstanding (15 Apr 2024) 413.24%
Shares short (prior month 15 Mar 2024) 48.4M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -96.11%
Operating margin (ttm)-35.53%

Management effectiveness

Return on assets (ttm)-6.73%
Return on equity (ttm)-16.86%

Income statement

Revenue (ttm)57.42M
Revenue per share (ttm)1.04
Quarterly revenue growth (yoy)19.90%
Gross profit (ttm)N/A
EBITDA -53.19M
Net income avi to common (ttm)-55.19M
Diluted EPS (ttm)-1.00
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)102.43M
Total cash per share (mrq)2.13
Total debt (mrq)49.16M
Total debt/equity (mrq)23.08%
Current ratio (mrq)5.39
Book value per share (mrq)4.43

Cash flow statement

Operating cash flow (ttm)-27M
Levered free cash flow (ttm)-13.89M